Published in Curr Drug Targets on October 01, 2009
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta (2010) 1.59
Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem (2011) 1.21
Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells. Biochem Res Int (2012) 0.83
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 3.24
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80
Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. J Clin Endocrinol Metab (2010) 2.70
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer (2005) 2.19
C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol (2005) 1.93
High rate of persistent hypothyroidism in a large-scale prospective study of postpartum thyroiditis in southern Italy. J Clin Endocrinol Metab (2010) 1.69
Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab (2010) 1.56
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Oncology (2011) 1.48
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer (2007) 1.43
Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol (2008) 1.41
Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol (2005) 1.25
Clinical diagnosis and treatment of ectopic pregnancy. Obstet Gynecol Surv (2013) 1.25
Radiofrequency ablation of 40 lung neoplasms: preliminary results. AJR Am J Roentgenol (2004) 1.23
Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res (2002) 1.22
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev (2010) 1.15
Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets (2011) 1.15
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol (2006) 1.14
Thyroid antibody positivity in the first trimester of pregnancy is associated with negative pregnancy outcomes. J Clin Endocrinol Metab (2011) 1.13
Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett (2011) 1.11
Complications of Uterine Fibroids and Their Management, Surgical Management of Fibroids, Laparoscopy and Hysteroscopy versus Hysterectomy, Haemorrhage, Adhesions, and Complications. Obstet Gynecol Int (2012) 1.11
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res (2013) 1.08
Microsurgical principles should be considered in studies addressing adhesion prevention: Cağlar et al. (2014). Arch Gynecol Obstet (2014) 1.07
Peripartum robotic-assisted laparoscopic hysterectomy after second-trimester pregnancy loss with placenta increta. Obstet Gynecol (2013) 1.07
[Importance of the molecular diagnosis in the screening of alpha-thalassemia]. Recenti Prog Med (2011) 1.07
Letter to the editor: 'Local tissue ischemia is not necessary for suture-induced adhesion formation' by Dr. Rajab. Langenbecks Arch Surg (2014) 1.07
TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? J Clin Oncol (2012) 1.07
Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol Biosyst (2012) 1.01
Target therapies in pancreatic carcinoma. Curr Med Chem (2014) 1.01
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol (2007) 0.99
Overexpression of nuclear NHERF1 in advanced colorectal cancer: association with hypoxic microenvironment and tumor invasive phenotype. Exp Mol Pathol (2012) 0.97
Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis. J Cell Physiol (2013) 0.97
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci (Landmark Ed) (2011) 0.97
Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. J Pharmacol Exp Ther (2006) 0.96
Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets (2012) 0.94
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging (2009) 0.94
Cancer survivorship: long-term side-effects of anticancer treatments of gastrointestinal cancer. Curr Opin Oncol (2015) 0.94
Role of gemcitabine in metastatic breast cancer patients: a short review. Breast (2007) 0.92
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol (2002) 0.92
Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology (2005) 0.92
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer (2009) 0.92
The role of hysteroscopy with eye-directed biopsy in postmenopausal women with uterine bleeding and endometrial atrophy. Menopause (2008) 0.91
Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci (2013) 0.91
Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer (2012) 0.90
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol (2012) 0.90
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther (2014) 0.89
The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology (2010) 0.89
Evaluation of neovessels in atherosclerotic plaques of rabbits using an albumin-binding intravascular contrast agent and MRI. J Magn Reson Imaging (2008) 0.88
High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med (2013) 0.88
Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation. Radiology (2003) 0.87
EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res (2010) 0.86
Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC Complement Altern Med (2013) 0.86
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients. Cancer Chemother Pharmacol (2005) 0.85
Tumor microvasculature observed using different contrast agents: a comparison between Gd-DTPA-Albumin and B-22956/1 in an experimental model of mammary carcinoma. MAGMA (2008) 0.85
Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score. Support Care Cancer (2011) 0.84
Advances in EGFR-directed therapy in head and neck cancer. Front Biosci (Schol Ed) (2011) 0.84
Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma. Tumori (2005) 0.84
Clinical Evidence Supporting the Role of Lonidamine for the Treatment of BPH. Rev Urol (2005) 0.83
Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine (2011) 0.83
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature. Mol Biosyst (2013) 0.83
A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history. Fam Cancer (2011) 0.83
Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist (2006) 0.82
Oncosuppressor methylation: a possible key role in colon metastatic progression. J Cell Physiol (2011) 0.82
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study. Lung Cancer (2011) 0.82
Effect of tamoxifen in an experimental model of breast tumor studied by dynamic contrast-enhanced magnetic resonance imaging and different contrast agents. Invest Radiol (2005) 0.82
p53 as the main traffic controller of the cell signaling network. Front Biosci (Landmark Ed) (2010) 0.82
Safe introduction of ancillary trocars in gynecological surgery: the "yellow island" anatomical landmark. Ann Ital Chir (2016) 0.82
Intrapartum sonography for fetal head asynclitism and transverse position: sonographic signs and comparison of diagnostic performance between transvaginal and digital examination. J Matern Fetal Neonatal Med (2012) 0.81
Adjuvant therapy in colon cancer. Oncology (2010) 0.81
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori (2012) 0.81
In vivo tracking of murine adipose tissue-derived multipotent adult stem cells and ex vivo cross-validation. Int J Mol Imaging (2013) 0.81
Is early stage endometrial cancer safely treated by laparoscopy? Complications of a multicenter study and review of recent literature. Surg Oncol (2009) 0.81
A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer. Clin Breast Cancer (2003) 0.81
Laparoscopy rein and a backward needle entrance. J Laparoendosc Adv Surg Tech A (2011) 0.81
Laparoscopy and natural orifice surgery: first entry safety surveillance step. JSLS (2011) 0.81
Conjugates of gadolinium complexes to bile acids as hepatocyte-directed contrast agents for magnetic resonance imaging. J Med Chem (2004) 0.81
Subfascial hematomas and hemoperitoneum after cesarean section: prevalence according to closure and non-closure of the parietal peritoneum. Gynecol Obstet Invest (2008) 0.81
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J Cancer Res Clin Oncol (2014) 0.81
Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale). Anticancer Res (2006) 0.80
Comparison between the use of the Joel-Cohen incision and its modification during Stark's cesarean section. J Matern Fetal Neonatal Med (2007) 0.80
Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. Breast J (2009) 0.80
Targeting EGFR in bilio-pancreatic and liver carcinoma. Front Biosci (Schol Ed) (2011) 0.80
Effects of visceral peritoneal closure on scar formation at cesarean delivery. Int J Gynaecol Obstet (2009) 0.80
Synchronous mandibular and giant parieto-occipital skull metastasis from hepatocellular carcinoma. Clin Gastroenterol Hepatol (2012) 0.80
Which role for EGFR therapy in breast cancer? Front Biosci (Schol Ed) (2012) 0.80
Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), a new intravascular contrast medium for MRI. Acad Radiol (2002) 0.80
Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit Rev Oncol Hematol (2012) 0.80
Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors. Fertil Steril (2008) 0.80
Combined modality treatments in pancreatic cancer. Expert Opin Ther Targets (2012) 0.80